S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
SPRB · Spruce Biosciences, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Spruce Biosciences, Inc (SPRB)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$42.44
+0.68
(+1.63%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$42.44
$41.19
$42.44
52-WEEK RANGE
$42.44
$38.06
$154.95
What's happening
- SPRB is up 1.63% today, trading at $42.44. — Live quote
- Volume today (1,979) is well below its 3-month average of 80,970. (Finnhub fundamentals)
- Reports earnings on 2026-11-09 (after market close), 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-6.68 actual vs. $-5.92 estimated (-12.9%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 9
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (15 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
SPRB
-52.67%
vs S&P 500
-65.45%
1-YEAR RETURN
SPRB
-72.17%
vs S&P 500
-86.73%
6-MONTH RETURN
SPRB
-39.28%
3-MONTH RETURN
SPRB
-9.74%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-6.68
Est. $-5.92
MISS -12.9%
2026-04-26 (Q1 2026)
$-8.94
Est. $-8.99
BEAT +0.6%
2026-01-26 (Q4 2025)
$-11.28
Est. $-8.15
MISS -38.5%
2025-10-26 (Q3 2025)
$-14.58
Est. $-14.21
MISS -2.6%
Valuation Measures & Ratios
Enterprise Value4$29.3M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)24.13
Price / Book71.77
EV4 / Revenue5.96
EV4 / EBITDA—
Profit Margin-1079.94%
Operating Margin-1143.37%
Return on Equity (ROE8)-155.40%
Return on Assets (ROA9)-101.67%
Avg Volume (3M)80,970
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $131.0M | $87.8M | $5.2M | $46.4K | $170.0K |
| P/E | -3.38 | -2.40 | -0.16 | -0.00 | -0.00 |
| Price/Sales | — | — | 8.64 | 0.02 | 0.04 |
| Price/Book | 1.56 | 2.54 | 0.97 | 0.00 | 0.01 |
| EV/Revenue | — | — | -8.19 | -6.96 | -5.72 |
| ROE | -46.31% | -105.59% | -612.53% | -257.66% | -283.99% |
| ROA | -37.70% | -65.14% | -215.44% | -155.64% | -137.50% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short431,541
Change from Prior Settlement+3.70%
% of Float—
Days to Cover (Short Ratio)4.53
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 10-Q, filed 2026-08-12; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -1079.9%. Finnhub fundamentals ↗
- Trailing 52-week price return is -72.2%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on SPRB
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 | $602.0K | $1.6M | $2.0M |
| Operating income | -$16.5M | -$12.0M | -$8.2M | -$2.7M | -$14.5M | -$9.4M | -$10.0M | -$12.6M |
| Net income | -$16.2M | -$12.3M | -$8.2M | -$2.1M | -$14.0M | -$8.7M | -$9.2M | -$11.6M |
| EPS (diluted) | $-6.68 | $-8.94 | $-14.58 | $-3.50 | $-23.95 | $-15.75 | $-16.73 | $-0.28 |
| EPS (basic) | $-6.68 | $-8.94 | $-14.58 | $-3.50 | $-23.95 | $-15.75 | $-16.73 | $-0.28 |
| Operating margin | — | — | — | — | — | -$1.6K | -$623 | -$631 |
| Net margin | — | — | — | — | — | -$1.4K | -$570 | -$581 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $102.9M | $56.2M | $53.0M | $15.3M | $21.8M | $31.6M | $45.2M | $65.1M |
| Total liabilities | $19.1M | $21.5M | $10.5M | $9.9M | $8.6M | $16.3M | $16.4M | $13.5M |
| Stockholders' equity | $83.7M | $34.6M | $42.5M | $5.4M | $13.2M | $15.3M | $28.8M | $51.6M |
| Total current assets | $101.2M | $55.0M | $52.1M | $14.5M | $21.0M | $30.6M | $44.2M | $63.6M |
| Total current liabilities | $11.0M | $11.8M | $10.1M | $9.4M | $8.1M | $15.7M | $15.2M | $11.9M |
| Cash & equivalents | $96.3M | $54.1M | $48.9M | $10.7M | $16.4M | $25.6M | $38.8M | $60.1M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Other current assets | $234.0K | $88.0K | $2.9M | $2.9M | $2.7M | $2.1M | $2.3M | $860.0K |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Other non-current assets | $1.2M | $539.0K | $243.0K | $62.0K | $64.0K | $204.0K | $69.0K | $531.0K |
| Accounts payable | $1.2M | $2.7M | $943.0K | $1.4M | $807.0K | $1.9M | $1.3M | $1.8M |
| Accrued liabilities | $7.3M | $8.1M | $9.1M | $7.5M | $6.3M | $12.4M | $12.3M | $7.7M |
| Deferred revenue (current) | — | — | — | — | — | — | $0 | $697.0K |
| Short-term debt | $2.5M | $1.0M | $0 | $539.0K | $943.0K | $1.3M | $1.6M | $1.6M |
| Long-term debt | $4.6M | $5.5M | $0 | $0 | $0 | $0 | $124.0K | $524.0K |
| Other non-current liabilities | — | — | $0 | $0 | $0 | $0 | $282.0K | $273.0K |
| Common stock & paid-in capital | $0 | $0 | $0 | $0 | $0 | $4.0K | $0 | $4.0K |
| Retained earnings | -$317.7M | -$301.5M | -$289.2M | -$274.6M | -$266.4M | -$264.3M | -$250.3M | -$226.7M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$22.1M | -$8.7M | -$6.5M | -$5.3M | -$8.8M | -$12.7M | -$20.7M | -$9.2M |
| Investing cash flow | -$135.0K | -$10.0K | — | — | $0 | $0 | $0 | $0 |
| Financing cash flow | $64.5M | $13.9M | $44.7M | -$402.0K | -$400.0K | -$411.0K | -$625.0K | -$405.0K |
| Free cash flow | -$22.3M | -$8.7M | — | — | -$8.8M | -$12.7M | -$20.7M | -$9.2M |
| Capital expenditures | $135.0K | $10.0K | — | — | $0 | $0 | $0 | $0 |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $871.0K | $689.0K | $1.7M | $415.0K | -$77.0K | $544.0K | $961.0K | $1.1M |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in accounts payable | -$1.4M | $1.7M | -$443.0K | $579.0K | -$1.1M | $584.0K | -$504.0K | $1.1M |
| Purchases of investments | — | — | — | — | — | — | $0 | $0 |
| Debt issued | $0 | $14.1M | — | — | $0 | $0 | — | — |
| Debt repaid | $0 | $0 | $841.0K | $405.0K | $406.0K | $405.0K | $406.0K | $405.0K |
| Tax withholding on stock comp | $0 | $10.0K | $831.0K | $0 | $0 | $0 | $233.0K | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0 | $4.9M | $10.1M | $0 | — |
| Operating income | -$36.5M | -$56.2M | -$52.0M | -$47.3M | -$42.1M |
| Net income | -$39.0M | -$53.0M | -$47.9M | -$46.2M | -$42.3M |
| EPS (diluted) | $-50.83 | $-96.40 | $-1.24 | $-1.96 | $-1.81 |
| EPS (basic) | $-50.83 | $-96.40 | $-1.24 | $-1.96 | $-1.81 |
| Operating margin | — | -$1.1K | -$515 | — | — |
| Net margin | — | -$1.1K | -$475 | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $53.0M | $45.2M | $103.9M | $85.6M | $126.5M |
| Total liabilities | $10.5M | $16.4M | $27.4M | $17.2M | $15.1M |
| Stockholders' equity | $42.5M | $28.8M | $76.5M | $68.5M | $111.4M |
| Total current assets | $52.1M | $44.2M | $102.2M | $83.6M | $91.9M |
| Total current liabilities | $10.1M | $15.2M | $24.5M | $12.4M | $8.9M |
| Cash & equivalents | $48.9M | $38.8M | $96.3M | $24.5M | $42.7M |
| Marketable securities (current) | — | — | $0 | $54.6M | $46.2M |
| Other current assets | $2.9M | $2.3M | $2.0M | $1.2M | $396.0K |
| Marketable securities (non-current) | — | — | — | $0 | $32.5M |
| Property, plant & equipment | — | — | — | — | $140.0K |
| Other non-current assets | $243.0K | $69.0K | $582.0K | $640.0K | $653.0K |
| Accounts payable | $943.0K | $1.3M | $3.3M | $1.4M | $2.8M |
| Accrued liabilities | $9.1M | $12.3M | $14.6M | — | — |
| Deferred revenue (current) | — | $0 | $4.9M | $0 | — |
| Short-term debt | $0 | $1.6M | $1.6M | $1.6M | $0 |
| Long-term debt | $0 | $124.0K | $1.7M | $3.3M | $4.9M |
| Other non-current liabilities | $0 | $282.0K | $236.0K | $161.0K | $73.0K |
| Common stock & paid-in capital | $0 | $0 | $4.0K | $3.0K | $3.0K |
| Retained earnings | -$289.2M | -$250.3M | -$197.2M | -$149.3M | -$103.1M |
| Accumulated other comprehensive income (loss) | — | — | $0 | -$558.0K | -$184.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$33.3M | -$56.0M | -$33.3M | -$41.7M | -$35.9M |
| Investing cash flow | — | $0 | $55.8M | $23.7M | -$79.2M |
| Financing cash flow | $43.5M | -$1.6M | $49.1M | -$241.0K | $643.0K |
| Free cash flow | — | -$56.0M | -$33.3M | -$41.7M | -$36.0M |
| Capital expenditures | — | $0 | $7.0K | $8.0K | $93.0K |
| Depreciation & amortization | — | — | — | — | $68.0K |
| Share-based compensation | $2.6M | $5.3M | $4.6M | $3.6M | $4.0M |
| Change in accounts payable | -$352.0K | -$2.0M | $1.9M | -$1.4M | -$805.0K |
| Purchases of investments | — | $0 | $11.9M | $36.8M | $79.1M |
| Debt issued | — | — | — | $0 | $5.0M |
| Debt repaid | $2.1M | $1.6M | $1.6M | $0 | $4.8M |
| Tax withholding on stock comp | $831.0K | $246.0K | $311.0K | $40.0K | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding SPRB as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-10-06 to 2026-06-30
Recent transactions
- Most recent: Szwarcberg Javier B. (CHIEF EXECUTIVE OFFICER) — Grant / award of 266 shares on 2026-06-30.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER | Grant / award | 2026-06-30 | 266 |
| Gharib Samir M. | PRESIDENT AND CFO | Option exercise | 2025-12-15 | 496 |
| Ways Douglas Kirk | Interim Chief Medical Officer | Option exercise | 2025-12-11 | 1,250 |
| Parkman Healthcare Partners LLC | 10% owner | Open market purchase | 2025-10-06 | 256 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-30 | Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER | Grant / award | 266 | $4.53 |
| 2025-12-31 | Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER | Grant / award | 4,690 | $4.53 |
| 2025-12-15 | Gharib Samir M. | PRESIDENT AND CFO | Option exercise | 496 | $0.00 |
| 2025-12-15 | Gharib Samir M. | PRESIDENT AND CFO | Tax withholding | 178 | $80.67 |
| 2025-12-15 | Gharib Samir M. | PRESIDENT AND CFO | Option exercise | 513 | $0.00 |
| 2025-12-15 | Gharib Samir M. | PRESIDENT AND CFO | Tax withholding | 184 | $80.67 |
| 2025-12-15 | Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER | Option exercise | 1,480 | $0.00 |
| 2025-12-15 | Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER | Tax withholding | 752 | $80.67 |
| 2025-12-15 | Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER | Option exercise | 1,196 | $0.00 |
| 2025-12-15 | Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER | Tax withholding | 608 | $80.67 |
| 2025-12-11 | Ways Douglas Kirk | Interim Chief Medical Officer | Option exercise | 1,250 | $0.00 |
| 2025-12-11 | Gharib Samir M. | PRESIDENT AND CFO | Option exercise | 1,900 | $0.00 |
| 2025-12-11 | Gharib Samir M. | PRESIDENT AND CFO | Tax withholding | 680 | $88.41 |
| 2025-12-11 | Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER | Option exercise | 4,950 | $0.00 |
| 2025-12-11 | Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER | Tax withholding | 2,194 | $88.41 |
| 2025-12-10 | Gharib Samir M. | PRESIDENT AND CFO | Option exercise | 514 | $0.00 |
| 2025-12-10 | Gharib Samir M. | PRESIDENT AND CFO | Tax withholding | 184 | $85.67 |
| 2025-12-10 | Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER | Option exercise | 1,196 | $0.00 |
| 2025-12-10 | Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER | Tax withholding | 428 | $85.67 |
| 2025-10-20 | Gharib Samir M. | PRESIDENT AND CFO | Option exercise | 2,053 | $0.00 |
| 2025-10-20 | Gharib Samir M. | PRESIDENT AND CFO | Tax withholding | 661 | $148.16 |
| 2025-10-20 | Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER | Option exercise | 4,784 | $0.00 |
| 2025-10-20 | Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER | Tax withholding | 1,539 | $148.16 |
| 2025-10-06 | Parkman Healthcare Partners LLC | 10% owner | Open market purchase | 256 | $17.91 |
| 2025-10-06 | Parkman Healthcare Partners LLC | 10% owner | Open market sale | 232 | $19.33 |
| 2025-10-06 | Parkman Healthcare Partners LLC | 10% owner | Open market sale | 25 | $17.46 |
| 2025-10-06 | Parkman Healthcare Partners LLC | 10% owner | Open market purchase | 256 | $17.91 |
| 2025-10-06 | Parkman Healthcare Partners LLC | 10% owner | Open market sale | 232 | $19.33 |
| 2025-10-06 | Parkman Healthcare Partners LLC | 10% owner | Open market sale | 25 | $17.46 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 22:46 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-12 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-12 | 8-K | 2026-08-12 | View on SEC.gov → |
| 2026-07-29 | 4 | 2026-07-27 | View on SEC.gov → |
| 2026-07-27 | 8-K | 2026-07-27 | View on SEC.gov → |
| 2026-07-09 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-05-26 | 4 | 2026-05-21 | View on SEC.gov → |
| 2026-05-26 | 4 | 2026-05-21 | View on SEC.gov → |
| 2026-05-26 | 4 | 2026-05-21 | View on SEC.gov → |
| 2026-05-26 | 4 | 2026-05-21 | View on SEC.gov → |
| 2026-05-26 | 4 | 2026-05-21 | View on SEC.gov → |
| 2026-05-26 | 8-K | 2026-05-21 | View on SEC.gov → |
| 2026-05-13 | 10-Q | 2026-03-31 | View on SEC.gov → |
Recent news
Headlines about SPRB (Spruce Biosciences, Inc.). Links open the publisher — we don’t host full articles.
-
Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference
Yahoo Finance · 2026-10-15 -
SPRB 8-K & SEC Filings
Yahoo! Finance Canada · 2026-10-15 -
SPRB 8-K & SEC Filings - Yahoo Finance
Yahoo! Finance Canada · 2026-10-15 -
Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting
Yahoo Finance · 2026-10-08 -
Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance · 2026-09-08 -
Spruce Biosciences stock gains after analyst backs regulatory progress
Yahoo Finance · 2026-08-27 -
Spruce Biosciences Announces Launch of MPS3BStudy.com
Yahoo Finance · 2026-08-26 -
Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026
Yahoo Finance · 2026-08-24
No headlines in this category right now — try “All”.